<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34642697</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2021.10.02.21264267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2021.10.02.21264267</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">B-cell depleting therapies may lead to protracted disease and prolonged viral shedding in individuals infected with SARS-CoV-2. Viral persistence in the setting of immunosuppression raises concern for viral evolution.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Amplification of sub-genomic transcripts for the E gene (sgE) was done on nasopharyngeal samples over the course of 355 days in a patient infected with SARS-CoV-2 who had previously undergone CAR T cell therapy and had persistently positive SARS-CoV-2 nasopharyngeal swabs. Whole genome sequencing was performed on samples from the patient's original presentation and 10 months later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over the course of almost a year, the virus accumulated a unique in-frame deletion in the amino-terminal domain of the spike protein, and complete deletion of ORF7b and ORF8, the first report of its kind in an immunocompromised patient. Also, minority variants that were identified in the early samples-reflecting the heterogeneity of the initial infection-were found to be fixed late in the infection. Remdesivir and high-titer convalescent plasma treatment were given, and the infection was eventually cleared after 335 days of infection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The unique viral mutations found in this study highlight the importance of analyzing viral evolution in protracted SARS-CoV-2 infection, especially in immunosuppressed hosts, and the implication of these mutations in the emergence of viral variants.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">We report an immunocompromised patient with persistent symptomatic SARS-CoV-2 infection for 335 days. During this time, the virus accumulated a unique in-frame deletion in the spike, and a complete deletion of ORF7b and ORF8 which is the first report of its kind in an immunocompromised patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nussenblatt</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD 20854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roder</LastName><ForeName>Allison E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Sanchita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Emmie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, DIR, NIAID, NIH, Hamilton, MT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Jung-Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banakis</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mushegian</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mederos</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-P&#xe9;rez</LastName><ForeName>Lizzette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, DIR, NIAID, NIH, Hamilton, MT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmore</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Center, NIH, Bethesda, MD 20854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brudno</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochenderfer</LastName><ForeName>James N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghedin</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Infect Dis. 2022 Apr 1;225(7):1118-1123. doi: 10.1093/infdis/jiab622</RefSource><PMID Version="1">34940844</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>7</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34642697</ArticleId><ArticleId IdType="pmc">PMC8509089</ArticleId><ArticleId IdType="doi">10.1101/2021.10.02.21264267</ArticleId><ArticleId IdType="pii">2021.10.02.21264267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zohar T. and Alter G., Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol, 2020. 20(7): p. 392&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278217</ArticleId><ArticleId IdType="pubmed">32514035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., et al., Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020. 183(1): p. 158&#x2013;168 e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatas A., et al., Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci, 2020. 59(5): p. 102871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333597</ArticleId><ArticleId IdType="pubmed">32694044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenig A., et al., Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol, 2021. 227: p. 108723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024218</ArticleId><ArticleId IdType="pubmed">33838340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley M.K., et al., Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study. Clin Infect Dis, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929077</ArticleId><ArticleId IdType="pubmed">33507235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., et al., SARS-CoV-2 evolution during treatment of chronic infection. Nature, 2021. 592(7853): p. 277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe, 2021. 2(1): p. e13&#x2013;e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato V.A., et al., Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell, 2020. 183(7): p. 1901&#x2013;1912 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B., et al., Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med, 2020. 383(23): p. 2291&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.T., et al., Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep, 2021. 34(6): p. 108728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudno J.N., et al., Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med, 2020. 26(2): p. 270&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781235</ArticleId><ArticleId IdType="pubmed">31959992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R., et al., Virological assessment of hospitalized patients with COVID-2019. Nature, 2020. 581(7809): p. 465&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., et al., The Architecture of SARS-CoV-2 Transcriptome. Cell, 2020. 181(4): p. 914&#x2013;921 e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179501</ArticleId><ArticleId IdType="pubmed">32330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Speranza E., et al., Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. Sci Transl Med, 2021. 13(578).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875333</ArticleId><ArticleId IdType="pubmed">33431511</ArticleId></ArticleIdList></Reference><Reference><Citation>Roder A.E., et al., Diversity and selection of SARS-CoV-2 minority variants in the early New York City outbreak. bioRxiv, 2021.</Citation></Reference><Reference><Citation>Bolger A.M., Lohse M., and Usadel B., Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, 2014. 30(15): p. 2114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. and Durbin R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield J., et al., Nextstrain: real-time tracking of pathogen evolution. Bioinformatics, 2018. 34(23): p. 4121&#x2013;4123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe S. and Buckland-Merrett G., Data, disease and diplomacy: GISAID&#x2019;s innovative contribution to global health. Glob Chall, 2017. 1(1): p. 33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., et al., A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol, 2020. 5(11): p. 1403&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., et al., Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol, 2021. 6(3): p. 415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845574</ArticleId><ArticleId IdType="pubmed">33514928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., et al., Moderate mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol, 2004. 4: p. 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446188</ArticleId><ArticleId IdType="pubmed">15222897</ArticleId></ArticleIdList></Reference><Reference><Citation>Worobey M., et al., The emergence of SARS-CoV-2 in Europe and North America. Science, 2020. 370(6516): p. 564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810038</ArticleId><ArticleId IdType="pubmed">32912998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G., et al., Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe, 2021. 29(5): p. 819&#x2013;833 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y.N., et al., SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East. Emerg Microbes Infect, 2020. 9(1): p. 1457&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473175</ArticleId><ArticleId IdType="pubmed">32543353</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y.C.F., et al., Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. mBio, 2020. 11(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7374062</ArticleId><ArticleId IdType="pubmed">32694143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachim A., et al., ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol, 2020. 21(10): p. 1293&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira F., Evolutionary dynamics of the SARS-CoV-2 ORF8 accessory gene. Infect Genet Evol, 2020. 85: p. 104525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467077</ArticleId><ArticleId IdType="pubmed">32890763</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B.E., et al., Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet, 2020. 396(10251): p. 603&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434477</ArticleId><ArticleId IdType="pubmed">32822564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>